drugset / Trial / NCT00992225

A Study of LY573636-sodium in Patients With Metastatic Breast Cancer

NCT00992225

Phase 2 Completed 43 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.

Timeline

Start
2009-09
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tasisulam Small molecule Intravenous

Indications